Oral anticoagulation in patients with atrial fibrillation and stage IV and V chronic kidney disease: a systematic review and meta-analysis

26 August 2022 (08:00 - 19:30)

Organised by:

Sign in to view the resources

Sign in for access options

About the speaker

Doctor Andres Miranda-Arboleda

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

4 More presentations in this session

Presentation thumbnail

Trends in oral anticoagulant use in patients with atrial fibrillation in Belgium from 2013 to 2019: a nationwide cohort study

Mr M. Grymonprez (Gent, BE)

Abstract Slides

Presentation thumbnail

The real-world effectiveness and safety of edoxaban treatment in 27,333 Global ETNA-AF programme patients with and without a history of heart failure

Professor J. Siller-Matula (Vienna, AT)

Abstract Slides

Presentation thumbnail

Potentially inappropriate prescribing and its demographic and clinical correlates in older adults with atrial fibrillation: a population-based study

Ms C. Amrouch (Ghent, BE)

Abstract Slides

Presentation thumbnail

The effect of eplerenone on the disease onset and progression of phospholamban cardiomyopathy in presymptomatic mutation carriers: results of the i-PHORECAST trial

Mr R. De Brouwer (Groningen, NL)

Abstract Slides

Access the full session

Session thumbnail

Anticoagulant therapy: real world use and clinical challenges

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022

You may be interested in

Congress Presentation

State-of-the-art lecture on pharmacotherapy for acute coronary syndromes

Webinar

Antithrombotic treatment for dual pathway inhibition in cardiovascular disease patients

Congress Presentation

Direct oral anticoagulants or warfarin in patients with left ventricular thrombus: a meta-analysis of randomized clinical trials

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources